Ballicules.com

Deferoxamine

DESFERAL

Pronunciation: de-fer-OX-a-meen

Deferoxamine ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Deferoxamine ballicule

What it isParenteral iron chelator; acute iron poisoning and transfusional overload.

Why this oneIt is the chelator for ACUTE iron poisoning, where oral agents are useless.

What limits itProlonged infusion is required, which is why oral agents replaced it for chronic overload. Hypotension if infused fast; ocular and auditory toxicity.

Deferoxamine molecular structure (skeletal formula)
Molecular structure: Deferoxamine

FDA label

FDA dosingPopulationStartTargetMax
Acute iron intoxication (IM, not in shock)Adults & peds1,000 mg, then 500 mg q4-12hper clinical response6,000 mg/24h
Acute iron intoxication (IV, cardiovascular collapse)Adults & peds1,000 mg at <=15 mg/kg/hr, then 500 mg q4-12h at <=125 mg/hrper clinical response6,000 mg/24h
Chronic iron overload (SC infusion)Adults & peds20-60 mg/kg/dayper ferritin40 mg/kg/day (peds); 60 mg/kg/day (adults)

Renal Contraindicated in severe renal disease/anuria. In renal impairment start at low end of dosing range; can cause increased creatinine, acute renal failure, renal tubular disorders.

Hepatic Undefined

Max 6,000 mg/24h in acute iron intoxication.

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy No human data; animal maternal toxicity and adverse fetal outcomes.

Lactation Breastfeeding not recommended during and for 1 week after last dose.

Cost

Deferoxamine (DESFERAL)
Strength#/mogeneric $/unitCostPlus
500 mginjper unitnot offered
2000 mginjper unitnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Deferoxamine is administered under clinical supervision and dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Generic entry2004

NO BOXED WARNINGS

Principal riskProlonged infusion; ocular and auditory toxicity

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger3 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityAgent-specific cardiovascular, neurologic or metabolic toxicity requires monitored use in poisoning or overload.

Open Deferoxamine in the interactive console ↗